Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Item 8.01 Other Events

On March29, 2017, Axsome Therapeutics,Inc. (the Company) issued a
press release announcing that Ladenburg Thalmann Co. Inc. (the
Underwriter), the sole book-running manager of its previously
disclosed public offering (the Offering), had exercised in full
its option to purchase 561,497 additional shares (the Shares) of
the Companys common stock, par value $0.0001 per share, granted
to the Underwriter in connection with the Offering.

On March30, 2017, the Company completed the sale of the Shares to
the Underwriter upon the exercise in full of its option to
purchase additional shares as part of the Offering. The Shares
were sold at a price to the public of $3.74 per Share and were
purchased by the Underwriter from the Company at a price of
$3.5156 per Share. The net proceeds to the Company from the sale
of the Shares were approximately $1.9 million after deducting the
underwriting discounts and commissions and estimated offering
expenses payable by the Company.

The aggregate net proceeds to the Company from the sale of the
4,304,813 shares of its common stock in the Offering were
approximately $14.6 million after deducting the underwriting
discounts and commissions and estimated offering expenses payable
by the Company.

The Offering was made by means of a written prospectus forming
part of a shelf registration statement on FormS-3 (Registration
Statement No.333-214859), previously filed by the Company with
the Securities and Exchange Commission (the SEC) and declared
effective by the SEC on December16, 2016, and a related
prospectus supplement.

A copy of the press release is attached hereto as Exhibit99.1 and
is incorporated by reference herein.

Neither the disclosures on this Form8-K nor the attached press
release shall constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any
such state or jurisdiction.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

About Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information

Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session 00.00 at 4.20 with 173,118 shares trading hands.